Main-blog-page-header

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



  • Comorbid High Blood Pressure in the Injured Individual: Part three

    by
    • Clinical Connection team
    | Oct 23, 2019
    Tag Icon
    Workers' Compensation, workers compensation, Clinical, Chronic Pain, Comorbidities
    Part three of our series discusses how injuries can often lead to comorbidity and complications that can lengthen the duration of treatment, delay return to work and increase costs.


  • Comorbid Mental Health Disorders in Workers’ Compensation & Auto No-fault: Part two

    by
    • Clinical Connection team
    | Oct 17, 2019
    Tag Icon
    Auto No-Fault, Workers' Compensation, mental health, comorbidity, Comorbidities
    Comorbid mental health issues can lengthen return-to-work times and increase costs in workers' comp and auto no-fault. Learn about the impact of mental health comorbidity and what steps to take to mitigate its effect.


  • Comorbidity and Injured Individuals: Part one

    by
    • Clinical Connection team
    • Medicare Insights
    | Oct 09, 2019
    Tag Icon
    MSA, Medicare Set-Aside, Medicare Insights, Comorbidities, clinical info, Clinical
    Comorbid conditions in workers’ compensation and auto no-fault can create a trifecta of negative outcomes and aggravate an already difficult situation for an injured individual. In Part one of our series on comorbidities, we will define what they are and describe the three ways comorbidities can make a bad situation worse.


  • New York Workers’ Compensation Board to offer training seminars for drug formulary process

    by
    • The Policy Matters team
    | Oct 08, 2019
    Tag Icon
    Formularies, formulary, PBM formulary, State Formulary, New York, Opioids, Government Affairs
    The New York Workers’ Compensation Board (WCB) has released an update on how payers and medical providers can comply with the drug formulary prior authorization process and access the medical portal.


  • Novartis halts distribution of ranitidine products, generic for Zantac®, as precaution during investigation of possible contamination

    by
    • Optum for Workers' Compensation
    | Sep 19, 2019
    Tag Icon
    Pharmacy, Clinical, recall, FDA
    On September 18, 2019, Novartis announced it is stopping the distribution of its Sandoz division’s ranitidine, generic for Zantac®, until further notice. This decision was made as a result of the U.S. Food and Drug Administration (FDA) statement on September 13 that low levels of a human carcinogen were found in some ranitidine products.


  • New federal workers’ comp opioid policy imposes additional limitations

    by
    • The Policy Matters team
    | Sep 17, 2019
    Tag Icon
    Government Affairs, Opioids, Department of Labor
    A new opioid policy imposing additional fill limitations and reducing the 60-day period for required prior approval has been announced by the U.S. Department of Labor, Office of Workers’ Compensation Programs (OWCP), Division of Federal Employees’ Compensation (DFEC).


  • DEA moving to increase marijuana research

    by
    • The Policy Matters team
    | Sep 11, 2019
    Tag Icon
    Medical Marijuana, DEA, Government Affairs
    The Drug Enforcement Administration (DEA) recently announced it is moving forward with efforts to increase scientific and medical research of marijuana.



Stay informed by receiving latest updates

Do you have a question about a blog post?